Last edition
News about "Bruton tyrosine kinase (BTK) inhibitor"
Lilly's Jaypirca Cuts Disease Progression Risk by 45 Percent in CLL/SLL
Lilly’s Jaypirca (pirtobrutinib) reduced the risk of disease progression or death by 45 percent when combined with a time-limited venetoclax regimen in previously treated CLL/SLL patients, according to phase 3 BRUIN CLL-322 trial results.
Bruton Tyrosine Kinase (BTK) Inhibitor | 15/06/2026 | By News Bureau
FDA Approves Expanded Use of Eli Lilly's Jaypirca in Relapsed or Refractory CLL/SLL
Eli Lilly’s Jaypirca (pirtobrutinib) is the only medicine in CLL or SLL that has been prospectively studied in a randomised trial of patients previously treated with a covalent BTK inhibitor.
Bruton Tyrosine Kinase (BTK) Inhibitor | 04/12/2025 | By Dineshwori | 258
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy